Who is at risk
- Smoking is the leading cause, and risk rises with how much and how long you smoked. Quitting at any age lowers it.
- Former smokers stay at elevated risk for years — which is why screening includes people who quit within the last 15 years.
- Radon exposure at home is the leading cause among people who never smoked. Test kits are inexpensive.
- Asbestos, diesel exhaust and some workplace exposures, especially combined with smoking.
- Family history of lung cancer, and prior radiation to the chest.
- People who never smoked get lung cancer too — roughly one in five women and one in ten men with lung cancer never smoked. A persistent symptom deserves attention regardless of smoking history.
Finding it early
The test is a low-dose CT scan (LDCT). It takes a few minutes, needs no needles, and uses far less radiation than a standard CT.
The U.S. Preventive Services Task Force recommends yearly LDCT screening for adults aged 50 to 80 who have a 20 pack-year smoking history and who currently smoke or quit within the past 15 years (USPSTF, 2021). A pack-year is one pack a day for a year — two packs a day for ten years is 20 pack-years.
Symptoms that should prompt a visit — a cough that will not go away or changes, coughing up blood, chest pain, shortness of breath, hoarseness, unexplained weight loss, or repeated chest infections. Screening is for people without symptoms; if you have symptoms, you need evaluation now, not a screening appointment.
Only about 22% of lung cancers are currently found while still localized (SEER, 2014–2020). That number is the single biggest opportunity in lung cancer.
How it’s diagnosed
A scan can find a spot; only tissue can name it. The usual path is imaging (CT, then often PET/CT) → a biopsy → testing of that tissue.
Biopsy may be done through a bronchoscope (a camera passed into the airways, often with ultrasound to sample lymph nodes), through the chest wall with a needle guided by CT, or surgically. Which one depends on where the spot sits.
Molecular and biomarker testing of that tissue is now standard for non-small cell lung cancer — looking for changes such as EGFR, ALK, ROS1, KRAS and others, plus PD-L1. These results can completely change which treatment is best, so it is reasonable to ask whether yours has been sent and when it will return.
Staging explained simply
Doctors describe stage with three letters — T for the tumor’s size and reach, N for lymph nodes, M for whether it has travelled. Those three combine into the stage number below. Small cell lung cancer is often described more simply as limited (fits in one radiation field) or extensive.
| Stage | What it means in plain words |
|---|---|
| Stage 0 | Abnormal cells only in the lining of the airway. Not yet invasive. |
| Stage I | A tumor confined to the lung, with no lymph nodes involved. Often curable with surgery or precision radiation alone. |
| Stage II | Larger, or spread to lymph nodes close to the lung. Usually treated with more than one type of therapy. |
| Stage III | Spread to lymph nodes in the middle of the chest, or into nearby structures. Usually chemotherapy with radiation, sometimes surgery, often followed by immunotherapy. |
| Stage IV | Spread to the other lung, the fluid around the lung, or distant organs. Treatment focuses on control and quality of life, and can work for a long time. |
Grading and biology
Stage is how far it has gone. Grade is how angry it looks. People mix these up constantly. Grade describes how abnormal the cells appear under the microscope and how fast they are likely to grow.
For lung cancer, the bigger fork is type: about 80–85% is non-small cell (adenocarcinoma, squamous cell, large cell) and the rest is small cell, which grows faster and is treated differently. Within non-small cell, the biomarker results described above often matter more to your plan than grade does.
How it’s treated
Surgery removes the tumor and is the classic approach for early-stage disease in someone fit enough for an operation.
Radiation does two very different jobs here. For early-stage tumors in people who cannot have surgery — or who choose not to — stereotactic body radiation therapy (SBRT) delivers a very precise, high dose in about three to five treatments, with no incision and no anesthesia. For stage III disease, radiation is given together with chemotherapy over several weeks. Radiation also relieves symptoms quickly when cancer causes pain, bleeding or blockage.
Chemotherapy, immunotherapy and targeted therapy treat the whole body. Targeted drugs are matched to a specific mutation; immunotherapy helps your own immune system recognize the cancer. Which applies depends on the biomarker testing.
Where CureRays fits: we are radiation specialists. We review your imaging, explain honestly whether radiation is the right tool for your situation, and coordinate with your surgeon and oncologist rather than replacing them.
What the guidelines say
In broad strokes: early-stage disease is treated with surgery or precision radiation; locally advanced disease with chemotherapy and radiation together, often followed by immunotherapy; and advanced disease with drug therapy chosen by biomarker results, with radiation added for symptoms. Small cell disease follows its own path, usually chemotherapy with radiation.
Your team will follow national guidelines such as those from the National Comprehensive Cancer Network (NCCN). The description above is a plain-language overview of the general approach, not the guideline itself — and your own plan may reasonably differ. NCCN publishes free NCCN Guidelines for Patients® written for exactly this purpose.
Outcomes and odds of cure
Source: NCI SEER Cancer Stat Facts: Lung and Bronchus Cancer, SEER 22 (excluding IL/MA), 2014–2020.
| When it is found | Share of cases | 5-year relative survival |
|---|---|---|
| Localized — still confined to the lung | 22% | 63.7% |
| Regional — spread to nearby lymph nodes | 21% | 35.9% |
| Distant — spread to other organs | 53% | 8.9% |
| Unstaged | 5% | 15.6% |
These are population statistics from the National Cancer Institute's SEER program. They describe large groups of people, not any one person, and they lag current treatment by several years — people treated today often do better than these figures suggest. They cannot predict what will happen to you.
Two things worth holding onto. First, lung cancer death rates have been falling about 4% a year (SEER, 2013–2022) — screening, better surgery, targeted drugs and immunotherapy are all contributing. Second, the figures above are dominated by the fact that most cases are still found late. Found early, this is frequently a curable cancer.
Side effects and how we watch for them
During radiation you may notice tiredness that builds over the course of treatment, irritation of the swallowing tube if it sits in the treated area, and sometimes a dry cough. Skin in the treated area can redden.
Later, the main things we watch for are inflammation of lung tissue (radiation pneumonitis), which usually appears within a few months and is treatable, and scarring in the treated area. Heart and swallowing structures are deliberately kept as low-dose as the plan allows.
How it is assessed: side effects are graded on a standard scale at every visit, so a change is measured rather than guessed at. Tell your team about new shortness of breath, fever or a cough that changes — early treatment of pneumonitis works well.
Follow-up, remission and survivorship
Remission means there is no detectable cancer. It is not the same as a guarantee, which is why surveillance continues.
After curative treatment, follow-up typically means a visit and a CT scan every few months for the first two to three years, then less often. Your team will give you the specific interval for your situation.
Survivorship is more than scans: quitting smoking after diagnosis still improves outcomes, breathing rehabilitation helps, vaccinations matter more, and screening for a second lung cancer continues. Ask for a written survivorship plan — who is watching what, how often, and whom to call.
Questions people actually ask
I quit smoking 20 years ago. Do I still need screening?
Current USPSTF criteria cover people who quit within the past 15 years. Beyond that, screening is not routinely recommended — but your risk is not zero, so any persistent symptom still deserves evaluation. Talk it through with your doctor.
I never smoked. Can I still get lung cancer?
Yes. Radon, workplace exposures, secondhand smoke and genetics all contribute, and some cases have no identified cause. Never-smokers are not screened routinely, which unfortunately means their cancers are often found later — so take a persistent cough or unexplained breathlessness seriously.
Is radiation instead of surgery a step down?
No. For selected early-stage tumors, SBRT is a recognized definitive treatment with its own strong evidence base, not a consolation prize. It is the standard option for people who cannot safely have an operation, and a reasonable discussion for some who can.
Will screening find things that turn out to be nothing?
Often, yes — small nodules are common and most are harmless. That is why screening programs follow a structured system for deciding which need a repeat scan and which need a biopsy, rather than acting on every finding.
Does radiation make you radioactive?
External radiation does not. You can be around family, including children, throughout treatment.
How long does treatment take?
SBRT for an early tumor is usually three to five sessions over a week or two. Radiation given with chemotherapy for stage III is usually daily on weekdays for about six weeks.
Informational only, not medical advice — confirm with your care team.
Short-term side effects of radiotherapy for lung cancer
Long-term side effects from lung cancer radiation
Go deeper on lung cancer
Read the full plain-language guide, or talk with our team about whether radiation has a role in your care.